You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

  • Technology appraisal guidance
  • Reference number: TA261
  • Published:  25 July 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee

6 Recommendations for further research

6.1

Further research on the clinical effectiveness of rivaroxaban compared with LMWH in patients with active cancer should be conducted.


Next page 7 Appraisal Committee members and NICE project team Previous page 5 Implementation